MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
Aligos Therapeutics, Inc. Common Stock

ALGS

#3397
Aligos Therapeutics, Inc. Common Stock
7.0300
+1.30%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
7.0300
7.0300
Intervallo Annuale
5.8200
13.6892
Variazione giornaliera
+1.30%
Variazione Mensile
-19.10%
Variazione di 6 mesi
-28.19%
Variazione Annuale
-28.19%
Chiusura Precedente
6.9400
Open
7.0300
Bid
Ask
Low
7.0300
High
7.0300
Volume
2
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. ALGS
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value 20202021202220232024 TTM

Notizie

Investing Investing
ALGS
2026.01.23
Aligos Therapeutics mantiene rating Buy da H.C. Wainwright grazie ai progressi di pevifoscorvir
Investing Investing
ALGS
2026.01.23
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Investing Investing
ALGS
2026.01.21
Il titolo di Aligos Therapeutics sale grazie ai progressi dello studio HBV di Fase 2
Investing Investing
ALGS
2026.01.21
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Investing Investing
ALGS
2026.01.21
Aligos reports progress on Phase 2 hepatitis B drug study
Investing Investing
ALGS
2026.01.13
Aligos Therapeutics nomina James Hassard come Chief Commercial Officer
Investing Investing
ALGS
2026.01.13
Aligos therapeutics appoints James Hassard as chief commercial officer
Investing Investing
GILD MDGL ALGS
2026.01.07
Aligos Therapeutics: UBS avvia copertura con rating Buy sul pipeline di malattie epatiche
Investing Investing
GILD MDGL ALGS
2026.01.07
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Investing Investing
ALGS
2025.12.11
Aligos riporta effetto sinergico di perdita di peso con agonista THR-β
Investing Investing
ALGS
2025.12.11
Aligos reports synergistic weight loss effect with THR-β agonist
Seeking Alpha Seeking Alpha
ALGS
2025.11.21
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd